MedTrace Logo

Predictive Immune Biomarkers for COVID-19 Pathogenesis

NCT04385108 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 565

Last updated 2025-03-30

No results posted yet for this study

Summary

The spectrum of the COVID-19 disease ranges from benign to asymptomatic to viral pneumopathy that can progress to acute respiratory distress syndrome (ARDS). The host-pathogen relationships and the physiopathological mechanisms underlying the clinical aggravation of COVID-19 patients remain misunderstood. The project aim is to create a prospective cohort of biological samples collected from well characterized COVID-19 patients. This project aims first to identify based on these samples an early immune signature predictive of clinical worsening of COVID-19 patients in order to improve their management, and secondarily to better understand pathophysiological mechanisms underlying the different phases of the disease in order to identify innovative therapeutic targets and vaccine perspectives.

Conditions

Interventions

BIOLOGICAL

Blood collection on admission and longitudinally

33 mL of blood collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)

BIOLOGICAL

Blood collection on their first consultation and 10 to 14 days later

33 mL of blood collected on their first consultation and 10 to 14 days later

Sponsors & Collaborators

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Guillaume MARTIN-BLONDEL, MD PhD · University Hospital, Toulouse

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-04
Primary Completion
2020-12-31
Completion
2021-12-24

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04385108 on ClinicalTrials.gov